Effectiveness of paroxetine in the treatment of acute major depression in adults: A systematic re-examination of published and unpublished data from randomized trials

CMAJ. Canadian Medical Association Journal

Volumn 178, Issue 3, 2008, Pages 296-305

  Barbui, Corrado ^a   Furukawa, Toshiaki A ^b   Cipriani, Andrea ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO;

ANXIETY; ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; HUMAN; MAJOR DEPRESSION; MEDICAL LITERATURE; MEDLINE; NEUROSIS; PUBLICATION; REGISTER; SUICIDAL TENDENCY; SUICIDE; SYSTEMATIC REVIEW;

EID: 38949183116     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.070693     Document Type: Article

References (32)

1. National Collaborating Centre for Mental Health. Depression (amended). Management of depression in primary and secondary care. London (UK): National Institute for Health and Clinical Excellence; 2007.
2. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002;3:69-86.
3. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005;331:155-7.
4. Moncrieff J. The antidepressant debate. Br J Psychiatry 2002;180:193-4.
5. Keller MB, Lavori PW. The adequacy of treating depression. J Nerv Ment Dis 1988;176:471-4.
6. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967;20:637-48.
7. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836-46.
8. Barbui C, Cipriani A. Evidence-based psychopharmacology: an agenda for the future. Evid Based Ment Health 2007;10:4-6.
9. Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: a meta-analysis. Can J Psychiatry 1996;41:613-6.
10. Williams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132:743-56.
11. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311-7.
12. Taylor MJ, Freemantle N, Geddes JR, et al. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006;63:1217-23.
13. Barbui C, Cipriani A. Publication bias in meta-analyses [letter]. Arch Gen Psychiatry 2007;64:868.
14. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
15. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-9.
16. Aursnes I, Tvete IF, Gaasemyr J, et al. Suicide attempts in clinical trials with paroxetine randomised against placebo. BMC Med 2005;3:14.
17. Aursnes I, Tvete IF, Gaasemyr J, et al. Even more suicide attempts in clinical trials with paroxetine randomised against placebo. BMC Psychiatry 2006;6:55.
18. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354:1896-900.
19. FDA briefing document for Dec. 13, 2006, meeting of Psychopharmacologic Drugs Advisory Committee. Rockville (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2006. p. 1-65. Available: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm (accessed 2007 Aug 29).
20. Norman GR. Issues in the use of change scores in randomized trials. J Clin Epidemiol 1989;42:1097-105.
21. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996; 313:1200.
22. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 2006;59:7-10.
23. Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.6. Chichester (UK): John Wiley & Sons; 2006 [updated 2006 Sept].
24. Cipriani A, Brambilla P, Furukawa T, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005;(4):CD004185.
25. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
26. Guyatt GH, Juniper EF, Walter SD, et al. Interpreting treatment effects in randomised trials. BMJ 1998;316:690-3.
27. Update April 5, 2006. Briefing document: Paroxetine adult suicidality analysis: major depressive disorder and non-major depressive disorder. GlaxoSmithKline; 2006. Available: http://us.gsk.com/docs-pdf/media-news/ briefing_doc.pdf (accessed 2007 Dec 14).
28. Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. BMJ 2005;330:373-4.
29. Murphy GM Jr, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61:1163-9.
30. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780-96.
31. Murphy GM Jr, Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-5.
32. Clarke MJ, Stewart LA. Meta-analyses using individual patient data. J Eval Clin Pract 1997;3:207-12.